|Panobinostat (Code C66948)|
|Terms & Properties|
Preferred Name: Panobinostat
Definition: A cinnamic hydroxamic acid analogue with potential antineoplastic activity. Panobinostat selectively inhibits histone deacetylase (HDAC), inducing hyperacetylation of core histone proteins, which may result in modulation of cell cycle protein expression, cell cycle arrest in the G2/M phase and apoptosis. In addition, this agent appears to modulate the expression of angiogenesis-related genes, such as hypoxia-inducible factor-1alpha (HIF-1a) and vascular endothelial growth factor (VEGF), thus impairing endothelial cell chemotaxis and invasion. HDAC is an enzyme that deacetylates chromatin histone proteins.
NCI-GLOSS Definition: A drug being studied in the treatment of cancer. It blocks enzymes needed for cells to grow and divide and may kill cancer cells. Panobinostat may also prevent the growth of new blood vessels that tumors need to grow. It is a type of histone deacetylase inhibitor and a type of antiangiogenesis agent.
Display Name: Panobinostat
NCI Metathesaurus Link: C1998098 (see NCI Metathesaurus info)
Synonyms & Abbreviations: (see Synonym Details)
External Source Codes:
|CAS Registry Number||404950-80-7 (see NLM ChemIDplus info)|
|FDA UNII Code||9647FM7Y3Z|
|PDQ Closed Trial Search ID||530790|
|PDQ Open Trial Search ID||530790 (check for NCI PDQ open clinical trial info)|
|Name||Value (qualifiers indented underneath)|
Additional Concept Data:
|Defined Fully by Roles: No|